NO20030958D0 - Pyrazole derivatives and their use as protein kinase inhibitors - Google Patents
Pyrazole derivatives and their use as protein kinase inhibitorsInfo
- Publication number
- NO20030958D0 NO20030958D0 NO20030958A NO20030958A NO20030958D0 NO 20030958 D0 NO20030958 D0 NO 20030958D0 NO 20030958 A NO20030958 A NO 20030958A NO 20030958 A NO20030958 A NO 20030958A NO 20030958 D0 NO20030958 D0 NO 20030958D0
- Authority
- NO
- Norway
- Prior art keywords
- protein kinase
- kinase inhibitors
- pyrazole derivatives
- pyrazole
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22941500P | 2000-08-31 | 2000-08-31 | |
| PCT/IB2001/001540 WO2002018346A1 (en) | 2000-08-31 | 2001-08-24 | Pyrazole derivatives and their use as protein kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20030958D0 true NO20030958D0 (en) | 2003-02-28 |
| NO20030958L NO20030958L (en) | 2003-02-28 |
Family
ID=22861151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20030958A NO20030958L (en) | 2000-08-31 | 2003-02-28 | Pyrazole derivatives and their use as protein kinase inhibitors |
Country Status (38)
| Country | Link |
|---|---|
| EP (1) | EP1313710A1 (en) |
| JP (1) | JP2004507526A (en) |
| KR (1) | KR20030027093A (en) |
| CN (1) | CN1518543A (en) |
| AP (1) | AP2001002266A0 (en) |
| AR (1) | AR035345A1 (en) |
| AU (1) | AU2001280009A1 (en) |
| BG (1) | BG107455A (en) |
| BR (1) | BR0113574A (en) |
| CA (1) | CA2420363A1 (en) |
| CR (1) | CR6881A (en) |
| CZ (1) | CZ2003468A3 (en) |
| DO (1) | DOP2001000243A (en) |
| DZ (1) | DZ3398A1 (en) |
| EA (1) | EA200300205A1 (en) |
| EC (1) | ECSP034480A (en) |
| EE (1) | EE200300085A (en) |
| GT (1) | GT200100179A (en) |
| HN (1) | HN2001000192A (en) |
| HR (1) | HRP20030140A2 (en) |
| HU (1) | HUP0302669A3 (en) |
| IL (1) | IL154016A0 (en) |
| IS (1) | IS6687A (en) |
| MA (1) | MA26946A1 (en) |
| MX (1) | MXPA03001785A (en) |
| NO (1) | NO20030958L (en) |
| NZ (1) | NZ523656A (en) |
| OA (1) | OA12368A (en) |
| PA (1) | PA8528101A1 (en) |
| PE (1) | PE20020470A1 (en) |
| PL (1) | PL360742A1 (en) |
| SK (1) | SK2002003A3 (en) |
| SV (1) | SV2002000618A (en) |
| TN (1) | TNSN01132A1 (en) |
| UY (1) | UY26909A1 (en) |
| WO (1) | WO2002018346A1 (en) |
| YU (1) | YU14703A (en) |
| ZA (1) | ZA200301064B (en) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| IL144144A0 (en) | 1999-01-13 | 2002-05-23 | Bayer Ag | Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6610677B2 (en) | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| EP1317449B1 (en) | 2000-09-15 | 2006-05-31 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6613776B2 (en) | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| ES2265450T3 (en) | 2000-12-21 | 2007-02-16 | Vertex Pharmaceuticals Incorporated | PIRAZOL COMPOUNDS USED AS INHIBITORS OF PROTEIN QUINASA. |
| DE60222286T2 (en) * | 2001-09-27 | 2008-06-19 | Laboratoires Serono S.A., Coinsins | PROCESS FOR INCREASING THE TESTOSTERONE MIRROR |
| JP4636486B2 (en) | 2002-02-11 | 2011-02-23 | バイエル、ファーマシューテイカルズ、コーポレイション | Arylurea with angiogenesis inhibitory activity |
| AU2003209119A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
| DE60320560T2 (en) * | 2002-07-17 | 2008-12-11 | Pfizer Italia S.R.L. | Heterocyclic pyrazole derivatives as kinase inhibitors |
| CA2501799C (en) | 2002-10-09 | 2008-06-17 | Pfizer Products Inc. | Pyrazole compounds for treatment of neurodegenerative disorders |
| EP1551842A1 (en) * | 2002-10-15 | 2005-07-13 | Smithkline Beecham Corporation | Pyradazine compounds as gsk-3 inhibitors |
| ATE410415T1 (en) * | 2003-02-27 | 2008-10-15 | Smithkline Beecham Corp | NEW CONNECTIONS |
| ES2305808T3 (en) | 2003-05-20 | 2008-11-01 | Bayer Healthcare Llc | DIARILURES WITH INHIBITING ACTIVITY OF QUINASAS. |
| CA2528496C (en) * | 2003-06-05 | 2011-04-12 | Elan Pharmaceuticals, Inc. | Acylated amino acid amidyl pyrazoles and related compounds |
| PL1651612T3 (en) | 2003-07-22 | 2012-09-28 | Astex Therapeutics Ltd | 3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
| CL2004001834A1 (en) | 2003-07-23 | 2005-06-03 | Bayer Pharmaceuticals Corp | COMPOUND 4- {4- [3- (4-CHLORO-3-TRIFLUOROMETILFENIL) -UREIDO] -3-FLUOROFENOXI} -PIRIDIN-2-METHYLAMIDE, RAF INHIBITOR, VEGFR, P38 AND PDGFR KINASES, ITS SALTS; PHARMACEUTICAL COMPOSIICON; PHARMACEUTICAL COMBINATION; AND ITS USE TO TREAT HYPERPROL DISORDERS |
| CA2532231A1 (en) * | 2003-07-25 | 2005-02-03 | Pfizer Inc. | Aminopyrazole compounds and use as chk1 inhibitors |
| DK1689721T3 (en) * | 2003-11-26 | 2010-09-20 | Pfizer Prod Inc | Aminopyrazole derivatives as GSK-3 inhibitors |
| US7244757B2 (en) * | 2004-04-01 | 2007-07-17 | Pfizer Inc | Pyrazole-amine compounds for the treatment of neurodegenerative disorders |
| JP2007533717A (en) * | 2004-04-21 | 2007-11-22 | アストラゼネカ アクチボラグ | Compound |
| MXPA06012394A (en) | 2004-04-30 | 2007-01-31 | Bayer Pharmaceuticals Corp | Substituted pyrazolyl urea derivatives useful in the treatment of cancer. |
| US7498342B2 (en) | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
| EP1781637A1 (en) | 2004-06-29 | 2007-05-09 | Rigel Pharmaceuticals, Inc. | 2-substituted quinoline compounds and their uses as inhibitors of the ige receptor signaling cascade |
| US7491720B2 (en) | 2004-10-29 | 2009-02-17 | Banyu Pharmaceutical Co., Ltd. | Aminopyridine derivatives having Aurora A selective inhibitory action |
| RU2007122485A (en) | 2004-11-17 | 2008-12-27 | Мийкана Терапьютикс | KINASE INHIBITORS |
| AR054425A1 (en) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | PIPERIDIN ADDITION SALTS 4-IL-ACID AMID 4- (2,6-DICLORO-BENZOILAMINO) 1H-PIRAZOL-3-CARBOXILICO. |
| US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
| EP1846394B1 (en) | 2005-02-04 | 2011-10-26 | AstraZeneca AB | Pyrazolylaminopyridine derivatives useful as kinase inhibitors |
| JPWO2006085685A1 (en) * | 2005-02-09 | 2008-06-26 | 武田薬品工業株式会社 | Pyrazole compounds |
| DE602006001515D1 (en) | 2005-02-16 | 2008-07-31 | Astrazeneca Ab | CHEMICAL COMPOUNDS |
| US20080287437A1 (en) | 2005-05-16 | 2008-11-20 | Astrazeneca Ab | Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors |
| EP1741708A1 (en) * | 2005-06-28 | 2007-01-10 | Sanofi-Aventis Deutschland GmbH | Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals |
| EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| CA2620333A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP1928456B1 (en) | 2005-09-30 | 2015-04-22 | Miikana Therapeutics, Inc. | Substituted pyrazole compounds |
| EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| US20080287475A1 (en) | 2005-10-28 | 2008-11-20 | Astrazeneca Ab | 4-(3-Aminopyrazole) Pyrimidine Derivatives for Use as Tyrosine Kinase Inhibitors in the Treatment of Cancer |
| JP2009513672A (en) | 2005-10-31 | 2009-04-02 | ブレインセルス，インコーポレイティド | GABA receptor-mediated regulation of neurogenesis |
| BRPI0619704A2 (en) | 2005-11-03 | 2011-10-11 | Vertex Pharma | compound, composition, method for inhibiting aurora kinase activity in a biological sample, method for treating a proliferative disorder and method for treating cancer |
| US7572809B2 (en) * | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| JP2009536669A (en) | 2006-05-09 | 2009-10-15 | ブレインセルス，インコーポレイティド | Neurogenesis by angiotensin regulation |
| WO2008047364A2 (en) * | 2006-10-18 | 2008-04-24 | Periness Ltd. | Method and pharmacological composition for the diagnosis and treatment of male sub-fertility |
| JP5406030B2 (en) * | 2006-10-21 | 2014-02-05 | アボット ゲーエムベーハー ウント カンパニー カーゲー | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| US7737149B2 (en) * | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
| AU2008208920A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or R(-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an NK1 |
| US20100190777A1 (en) | 2007-07-17 | 2010-07-29 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| WO2009017453A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958 |
| ES2569734T3 (en) | 2007-09-21 | 2016-05-12 | Array Biopharma, Inc. | Pyridin-2-yl-thiourea and pyridin-2-yl-amine derivatives as intermediates for the preparation of glucokinase activating pyridin-2-yl-amino-1,2,4-thiadiazoles |
| JPWO2009130900A1 (en) * | 2008-04-24 | 2011-08-11 | 日本曹達株式会社 | Oxime derivatives, intermediate compounds and plant disease control agents |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| MX349923B (en) | 2009-04-03 | 2017-08-21 | Hoffmann La Roche | Propane- i-sulfonic acid {3- [5- (4 -chloro-phenyl) -1h-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof. |
| WO2011041634A1 (en) * | 2009-10-02 | 2011-04-07 | Vertex Pharmaceuticals Incorporated | Pyrazole inhibitors of phosphatidylinositol 3-kinase |
| JP2013510166A (en) | 2009-11-06 | 2013-03-21 | プレキシコン インコーポレーテッド | Compounds, methods and applications for kinase regulation |
| EP2621914B1 (en) | 2010-09-27 | 2016-12-28 | Abbott GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| US9090592B2 (en) | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| PL2672967T3 (en) | 2011-02-07 | 2019-04-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| AR085279A1 (en) | 2011-02-21 | 2013-09-18 | Plexxikon Inc | SOLID FORMS OF {3- [5- (4-CHLORINE-PHENYL) -1H-PIRROLO [2,3-B] PIRIDINA-3-CARBONIL] -2,4-DIFLUOR-PHENIL} -AMIDE OF PROPANE ACID-1- SULFONIC |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| CA2921265C (en) | 2013-08-16 | 2021-03-23 | Merck Patent Gmbh | 3-substituted cyclopentylamine derivatives |
| CN106580986B (en) * | 2016-11-28 | 2017-09-15 | 王保亮 | A kind of pharmaceutical composition for treating teen bra |
| US11084825B2 (en) | 2018-12-31 | 2021-08-10 | Biomea Fusion, Llc | Substituted pyridines as irreversible inhibitors of menin-MLL interaction |
| EP3906029A4 (en) | 2018-12-31 | 2022-09-21 | Biomea Fusion, LLC | Inhibitors of menin-mll interaction |
| AU2020213761C1 (en) * | 2019-01-31 | 2023-08-10 | Pfizer Inc. | 3-carbonylamino-5-cyclopentyl-1 Fi-pyrazole compounds having inhibitory activity on CDK2 |
| TW202229268A (en) * | 2020-12-22 | 2022-08-01 | 大陸商上海拓界生物醫藥科技有限公司 | Cdk2 inhibitor and preparation method thereof |
| US11932648B2 (en) | 2021-06-28 | 2024-03-19 | Blueprint Medicines Corporation | CDK2 inhibitors |
| WO2023274397A1 (en) * | 2021-07-01 | 2023-01-05 | 上海拓界生物医药科技有限公司 | Cdk2 inhibitor, preparation method therefor and use thereof |
| TW202325280A (en) * | 2021-11-09 | 2023-07-01 | 大陸商上海拓界生物醫藥科技有限公司 | An aminopyrazole derivative, preparation method and use thereof |
| WO2023092088A1 (en) * | 2021-11-19 | 2023-05-25 | Blueprint Medicines Corporation | Cdk2 inhibitors and methods of making and using same |
| WO2023239629A1 (en) * | 2022-06-06 | 2023-12-14 | Plexium, Inc. | Compounds and pharmaceutical compositions that degrade cdk2 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ299156B6 (en) * | 1997-12-22 | 2008-05-07 | Bayer Corporation | Substituted heterocyclic ureas, pharmaceutical compositions in which they are comprised and their use |
| KR100579792B1 (en) * | 1998-05-13 | 2006-05-12 | 동화약품공업주식회사 | Novel 2,5-pyridinedicarboxylic acid derivatives |
| GB9811427D0 (en) * | 1998-05-29 | 1998-07-22 | Zeneca Ltd | Chemical compounds |
| WO2001007411A1 (en) * | 1999-07-26 | 2001-02-01 | Banyu Pharmaceutical Co., Ltd. | Biarylurea derivatives |
| US6387900B1 (en) * | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
| AP2002002442A0 (en) * | 1999-08-12 | 2002-03-31 | Pharmacia Italia Spa | 3(5)-Amino-pyrazole derivatives, process for their preparation and their preparation and their use as antitumor agents. |
| ES2253266T3 (en) * | 1999-11-30 | 2006-06-01 | Pfizer Products Inc. | 2,4-DIAMINOPIRIMIDINE COMPOUNDS USED AS IMMUNOSUPPRESSORS. |
| MXPA02010222A (en) * | 2000-04-18 | 2003-05-23 | Agouron Pharma | Pyrazoles for inhibiting protein kinase. |
-
2001
- 2001-08-24 CN CNA018147615A patent/CN1518543A/en active Pending
- 2001-08-24 EA EA200300205A patent/EA200300205A1/en unknown
- 2001-08-24 WO PCT/IB2001/001540 patent/WO2002018346A1/en not_active Application Discontinuation
- 2001-08-24 JP JP2002523464A patent/JP2004507526A/en active Pending
- 2001-08-24 YU YU14703A patent/YU14703A/en unknown
- 2001-08-24 CA CA002420363A patent/CA2420363A1/en not_active Abandoned
- 2001-08-24 AP APAP/P/2001/002266A patent/AP2001002266A0/en unknown
- 2001-08-24 PL PL36074201A patent/PL360742A1/en not_active Application Discontinuation
- 2001-08-24 KR KR10-2003-7002894A patent/KR20030027093A/en not_active Application Discontinuation
- 2001-08-24 IL IL15401601A patent/IL154016A0/en unknown
- 2001-08-24 HU HU0302669A patent/HUP0302669A3/en unknown
- 2001-08-24 BR BR0113574-0A patent/BR0113574A/en not_active IP Right Cessation
- 2001-08-24 CZ CZ2003468A patent/CZ2003468A3/en unknown
- 2001-08-24 NZ NZ523656A patent/NZ523656A/en unknown
- 2001-08-24 DZ DZ013398A patent/DZ3398A1/en active
- 2001-08-24 MX MXPA03001785A patent/MXPA03001785A/en not_active Application Discontinuation
- 2001-08-24 OA OA1200300050A patent/OA12368A/en unknown
- 2001-08-24 AU AU2001280009A patent/AU2001280009A1/en not_active Abandoned
- 2001-08-24 SK SK200-2003A patent/SK2002003A3/en not_active Application Discontinuation
- 2001-08-24 EE EEP200300085A patent/EE200300085A/en unknown
- 2001-08-24 EP EP01958287A patent/EP1313710A1/en not_active Withdrawn
- 2001-08-27 UY UY26909A patent/UY26909A1/en not_active Application Discontinuation
- 2001-08-28 HN HN2001000192A patent/HN2001000192A/en unknown
- 2001-08-29 PE PE2001000872A patent/PE20020470A1/en not_active Application Discontinuation
- 2001-08-29 DO DO2001000243A patent/DOP2001000243A/en unknown
- 2001-08-29 AR ARP010104115A patent/AR035345A1/en unknown
- 2001-08-30 TN TNTNSN01132A patent/TNSN01132A1/en unknown
- 2001-08-30 GT GT200100179A patent/GT200100179A/en unknown
- 2001-08-30 SV SV2001000618A patent/SV2002000618A/en unknown
- 2001-08-31 PA PA20018528101A patent/PA8528101A1/en unknown
-
2003
- 2003-01-13 BG BG107455A patent/BG107455A/en unknown
- 2003-01-15 CR CR6881A patent/CR6881A/en not_active Application Discontinuation
- 2003-01-16 IS IS6687A patent/IS6687A/en unknown
- 2003-02-07 ZA ZA200301064A patent/ZA200301064B/en unknown
- 2003-02-17 EC EC2003004480A patent/ECSP034480A/en unknown
- 2003-02-21 MA MA27050A patent/MA26946A1/en unknown
- 2003-02-26 HR HR20030140A patent/HRP20030140A2/en not_active Application Discontinuation
- 2003-02-28 NO NO20030958A patent/NO20030958L/en not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20030958L (en) | Pyrazole derivatives and their use as protein kinase inhibitors | |
| DK1337527T3 (en) | Indolylmaleinimide derivatives as protein kinase C inhibitors | |
| NO20026010D0 (en) | Substituted quinazoline derivatives and their use as inhibitors | |
| NO20023713D0 (en) | 2-benzothiazolyl-urea derivatives and their use as protein kinase inhibitors | |
| DK1480962T3 (en) | 5-Phenylthiazole derivatives and their use as P1-3 kinase inhibitors | |
| DK1268431T3 (en) | 3-Cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | |
| NO20030779D0 (en) | Condensed pyrazole derivatives which are protein kinase inhibitors | |
| NO20053356L (en) | Aminindazole derivatives and their use as kinase inhibitors. | |
| NO20032703D0 (en) | Pyrazole compounds useful as protein kinase inhibitors | |
| NO20031188L (en) | Pyrazole compounds useful as protein kinase inhibitors | |
| NO20025884D0 (en) | 2-aminothiazoline derivatives and their use as NO synthase inhibitors | |
| NO20030813L (en) | Biphenyl derivatives and their use as integrin inhibitors | |
| NO20025885D0 (en) | 4,5-dihydro-thiazol-2-ylamine derivatives and their use as NO synthase inhibitors | |
| DK1317448T4 (en) | Pyrazole compounds useful as protein kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |